Stockscreener 앱 받기
30.39
1.37%
0.41
전일 마감가:
$29.98
열려 있는:
$30.21
하루 거래량:
532.59K
Relative Volume:
0.59
시가총액:
$1.40B
수익:
$203.27M
순이익/손실:
$-4.66M
주가수익비율:
-303.90
EPS:
-0.1
순현금흐름:
$3.47M
1주 성능:
-8.79%
1개월 성능:
+26.15%
6개월 성능:
+202.69%
1년 성능:
+110.90%
1일 변동 폭
$29.73
$30.76
1주일 범위
$28.88
$33.14
52주 변동 폭
$9.215
$34.24
Axogen Inc Stock (AXGN) Company Profile
명칭
Axogen Inc
전화
(386) 462-6817
주소
13631 PROGRESS BLVD., ALACHUA, FL
AXGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
30.39 | 1.38B | 203.27M | -4.66M | 3.47M | -0.10 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-01 | 개시 | Mizuho | Outperform |
| 2025-03-17 | 개시 | Lake Street | Buy |
| 2024-07-01 | 개시 | Raymond James | Outperform |
| 2022-11-11 | 재개 | Jefferies | Buy |
| 2022-05-09 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 개시 | Guggenheim | Buy |
| 2020-06-16 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-05-07 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | 개시 | Canaccord Genuity | Buy |
| 2018-03-02 | 재확인 | Lake Street | Buy |
| 2018-01-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2017-11-30 | 개시 | Jefferies | Buy |
| 2017-11-21 | 재확인 | Lake Street | Buy |
| 2017-07-31 | 개시 | Leerink Partners | Outperform |
| 2017-06-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-06 | 개시 | ROTH Capital | Buy |
| 2016-11-22 | 업그레이드 | Lake Street | Hold → Buy |
| 2016-11-07 | 재확인 | Wedbush | Outperform |
| 2016-11-03 | 다운그레이드 | Lake Street | Buy → Hold |
| 2016-08-04 | 재확인 | Wedbush | Outperform |
| 2014-05-14 | 개시 | Dawson James | Buy |
| 2013-10-31 | 재확인 | Ladenburg Thalmann | Buy |
모두보기
Axogen Inc 주식(AXGN)의 최신 뉴스
Is Axogen Stock Built to Withstand More Downside? - Trefis
Can Axogen Stock Recover If Markets Fall? - Trefis
Leerink Partners raises AxoGen stock price target to $40 on BLA approval - Investing.com Canada
Insider Sell: Marc Began Sells Shares of Axogen Inc (AXGN) - GuruFocus
Trade Alert: President Of Axogen Michael Dale Has Sold Stock - simplywall.st
Armistice Capital LLC Boosts Holdings in AxoGen, Inc. $AXGN - MarketBeat
Michael Dale Sells 61,463 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
Paul Thomas Sells 21,399 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
John Johnson Sells 21,686 Shares of AxoGen (NASDAQ:AXGN) Stock - MarketBeat
AxoGen (NASDAQ:AXGN) CFO Sells $454,053.72 in Stock - MarketBeat
Insider Sell: Paul Thomas Sells 21,399 Shares of Axogen Inc (AXG - GuruFocus
Axogen Insider Sold Shares Worth $1,390,393, According to a Recent SEC Filing - marketscreener.com
Axogen Insider Sold Shares Worth $633,710, According to a Recent SEC Filing - marketscreener.com
Legal & General Group Plc Purchases 83,175 Shares of AxoGen, Inc. $AXGN - MarketBeat
CFO Hartley Files To Sell 14,387 Of Axogen Inc [AXGN] - TradingView
H.C. Wainwright raises AxoGen stock price target to $39 after FDA approval - Investing.com Nigeria
AxoGen (NASDAQ:AXGN) Trading Down 4.7%What's Next? - MarketBeat
H.C. Wainwright raises AxoGen stock price target to $39 after FDA approval By Investing.com - Investing.com South Africa
(AXGN) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
AxoGen approves new CFO compensation and agreement - MSN
Prudential Financial Inc. Trims Stake in AxoGen, Inc. $AXGN - MarketBeat
Axogen (AXGN): Reassessing Valuation After FDA Biologics License Approval for AVANCE - Sahm
Axogen (AXGN) Price Target Increased by 18.26% to 34.58 - Nasdaq
AxoGen Secures FDA Approval for Avance Nerve Scaffold - The Globe and Mail
Canaccord Genuity Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
AxoGen Approves New CFO Compensation and Agreement - TipRanks
AXGN: Canaccord Genuity Raises Price Target to $37, Maintains Bu - GuruFocus
AXGN Sees Enhanced Price Target by HC Wainwright & Co. Analyst Y - GuruFocus
Three Stocks Estimated To Be Trading Below Intrinsic Value In December 2025 - simplywall.st
AxoGen (NASDAQ:AXGN) Shares Gap UpHere's What Happened - MarketBeat
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity - Investing.com Nigeria
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity By Investing.com - Investing.com South Africa
AxoGen, Inc. $AXGN Shares Sold by Panagora Asset Management Inc. - MarketBeat
Will Axogen Inc. stock maintain growth storyWeekly Trend Summary & Real-Time Stock Price Movement Reports - Newser
Jefferies Raises Axogen (AXGN) Price Target to $36, Maintains Bu - GuruFocus
Jefferies Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
AXGN: Lake Street Maintains "Buy" Rating and Raises Price Target to $40.00 | AXGN Stock News - GuruFocus
Why Is Axogen Stock Soaring Thursday?Axogen (NASDAQ:AXGN) - Benzinga
AxoGen stock price target raised to $36 from $27 at Raymond James By Investing.com - Investing.com South Africa
AxoGen stock price target raised to $36 from $27 at Raymond James - Investing.com Nigeria
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval By Investing.com - Investing.com Nigeria
Why Is AXGN Stock Rising Today? - Stocktwits
Axogen's Avance secures FDA approval for nerve repair - BioWorld MedTech
FDA approves Axogen's nerve repair graft - Reuters
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval - Investing.com
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval - Investing.com Nigeria
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval By Investing.com - Investing.com South Africa
Axogen, Inc. (AXGN) Stock: FDA Approval Boosts Avance as a Leading Nerve Repair Solution - parameter.io
Mizuho Begins Coverage on AxoGen (NASDAQ:AXGN) - MarketBeat
FDA Biologic Approval For AVANCE Might Change The Case For Investing In Axogen (AXGN) - simplywall.st
Axogen stock soars after FDA approval for nerve repair product By Investing.com - Investing.com South Africa
Axogen Inc (AXGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.28%
자본화:
|
볼륨(24시간):